Caladrius生物科学
CLBS

股本结构

单位：万股
公告日期 2022-08-04 2022-05-05 2022-04-21 2022-05-05 2022-03-22 2022-03-22
证券总股本 6058.32 6051.85 6052.16 6053.31 6053.31 5978.97
普通股本 6058.32 6051.85 6052.16 6053.31 6053.31 5978.97
优先股 1.00 未披露 未披露 1.00 未披露 未披露
其他 未披露 未披露 未披露 未披露 未披露 未披露
变动日期 2022-06-30 2022-05-05 2022-04-21 2022-03-31 2022-03-22 2021-12-31
注释：中概股证券总股本=普通股股本/ 存托凭证比例

历史变动

公告日期 变动后普通股本（万股） 变动后优先股（万股） 变动原因 变动日期
2022-09-14 403.89 未披露
更多>>
Subsequent to the stockholders’ approval, the Caladrius Board of Directors approved a reverse stock split of Caladrius’ common stock at a ratio of one new share for every fifteen shares outstanding. The reverse stock split will become effective today, September 14, 2022, at 5:00pm EST.
2022-09-15
2022-08-04 6058.32 1.00
更多>>
From March 31, 2022 to June 30, 2022 Net proceeds from issuance of common stock Share-based compensation
2022-06-30
2022-05-05 6051.85 未披露 定期报告 2022-05-05
2022-04-21 6052.16 未披露 定期报告 2022-04-21
2022-05-05 6053.31 1.00
更多>>
From December 31, 2021 to March 31, 2022 Share-based compensation
2022-03-31
2022-03-22 6053.31 未披露 定期报告 2022-03-22
2022-03-22 5978.97 1.00
更多>>
From December 31, 2020 to December 31, 2021 Share-based compensation Net proceeds from issuance of common stock and warrants Proceeds from option exercises
2021-12-31
2021-11-04 5977.99 1.00
更多>>
From June 30, 2021 to September 30, 2021 Share-based compensation
2021-09-30
2021-08-05 5951.75 1.00
更多>>
From March 31, 2021 to June 30, 2021 Net proceeds from issuance of common stock
2021-06-30
2021-05-06 5949.90 1.00
更多>>
from December 31, 2020 to March 31, 2021 Share-based compensation Net proceeds from issuance of common stock and warrants Proceeds from option exercises
2021-03-31
2021-02-25 5950.53 未披露 定期报告 2021-02-25
2021-02-17 5843.48 未披露
更多>>
1.Common Stock offered by this prospectus supplement 24,906,134 shares. 2.Unless the company indicate otherwise, all information in this prospectus is based on 31,895,977 shares of Common Stock, which includes 19,395,977 shares of Common Stock outstanding as of September 30, 2020, plus 12,500,000 shares of Common Stock that were issued in a private placement offering on January 21, 2021.
2021-02-17
2021-01-29 3296.65 未披露 定期报告 2021-01-29
2021-02-25 1937.83 1.00
更多>>
From December 31, 2019 to December 31, 2020 Share-based compensation Net proceeds from issuance of common stock and warrants
2020-12-31
2020-11-05 1939.60 1.00
更多>>
From June 30, 2020 to September 30, 2020 Share-based compensation Net proceeds from issuance of common stock and warrants
2020-09-30
2020-08-13 1932.31 未披露 定期报告 2020-08-13
2020-08-13 1558.52 1.00
更多>>
From March 31, 2020 to June 30, 2020 Share-based compensation Net proceeds from issuance of common stock and warrants
2020-06-30
2020-06-19 1555.21 1.00 定期报告 2020-06-15
2020-05-28 1492.53 未披露
更多>>
1.Common Stock offered by this prospectus supplement 2,084,850 shares of Common Stock 2. based on 12,840,403 shares of Common Stock, which includes 10,627,691 shares of Common Stock outstanding as of March 31, 2020, plus 2,162,166 shares of Common Stock that were issued in a registered direct offering on April 23, 2020.
2020-05-28
2020-05-07 1284.04 未披露 定期报告 2020-05-06
2020-04-27 1278.99 未披露
更多>>
1.Common Stock offered by this prospectus supplement 2,162,166 shares of Common Stock 2.based on 10,627,691 shares of Common Stock outstanding as of March 31, 2020
2020-04-27
2020-04-29 1062.77 未披露 定期报告 2020-04-20
2020-05-07 1063.88 1.00
更多>>
from December 31, 2019 to March 31, 2020 Share-based compensation
2020-03-31
2020-03-05 1063.88 未披露 定期报告 2020-03-05
2020-03-05 1052.87 1.00
更多>>
from December 31, 2018 to December 31, 2019 Share-based compensation Net proceeds from issuance of common stock
2019-12-31
2019-11-06 1039.99 未披露 定期报告 2019-11-05
2019-11-06 1041.10 1.00
更多>>
From June 30, 2019 to September 30, 2019 Share-based compensation
2019-09-30
2019-08-08 1040.17 未披露 定期报告 2019-08-08
2019-08-08 1041.28 1.00
更多>>
From March 31, 2019 to June 30, 2019 Net proceeds from issuance of common stock
2019-06-30
2019-05-09 1038.22 未披露 定期报告 2019-05-08
2019-05-09 1039.33 1.00
更多>>
from December 31, 2018 to March 31, 2019 Share-based compensation Net proceeds from issuance of common stock
2019-03-31
2019-03-14 995.05 未披露 定期报告 2019-03-08
2019-03-14 986.57 1.00
更多>>
from December 31, 2017 to December 31, 2018 Share-based compensation Net proceeds from issuance of common stock Proceeds from option exercises
2018-12-31
2018-11-08 984.20 未披露 定期报告 2018-11-07
2018-11-08 985.31 1.00
更多>>
From December 31, 2017 to September 30, 2018 Share-based compensation Net proceeds from issuance of common stock Proceeds from option exercises
2018-09-30
2018-08-09 972.54 未披露 定期报告 2018-08-07
2018-07-24 972.43 1.00 定期报告 2018-07-23
2018-08-09 973.54 1.00
更多>>
From December 31, 2017 to June 30, 2018 Share-based compensation Net proceeds from issuance of common stock Proceeds from option exercises
2018-06-30
2018-04-24 956.99 1.00 定期报告 2018-04-23
2018-04-24 956.99 未披露 定期报告 2018-04-19
2018-05-10 957.47 1.00
更多>>
From December 31, 2017 to March 31, 2018 Share-based compensation Proceeds from option exercises
2018-03-31
2018-03-22 955.27 未披露 定期报告 2018-03-22
2018-03-22 948.39 1.00
更多>>
from December 31, 2016 to December 31, 2017 Share-based compensation Net proceeds from issuance of common stock Proceeds from option exercises
2017-12-31
2017-11-09 947.09 未披露 定期报告 2017-11-06
2017-11-09 942.70 1.00
更多>>
from December 31, 2016 to September 30, 2017 Share-based compensation Net proceeds from issuance of common stock Proceeds from option exercises
2017-09-30
2017-08-10 891.26 1.00
更多>>
From December 31, 2016 to June 30, 2017 Share-based compensation Net proceeds from issuance of common stock Proceeds from option exercises
2017-06-30
2017-05-15 894.09 未披露 定期报告 2017-05-10
2017-04-11 894.25 未披露 定期报告 2017-04-06
2017-05-15 895.33 1.00
更多>>
From December 31, 2016 to March 31, 2017 Share-based compensation Net proceeds from issuance of common stock
2017-03-31
2017-03-17 830.83 未披露 定期报告 2017-03-16
2017-03-17 820.58 1.00
更多>>
From December 31, 2015 to December 31, 2016 Share-based compensation Net proceeds from issuance of common stock Caladrius Biosciences, Inc., a cell therapy company combining an industry-leading development and manufacturing services provider (PCT) with a select therapeutic development pipeline, announces today that as of 5:00 p.m., Eastern Time, on July 27, 2016 it will effect a 1-for-10 reverse stock split of its outstanding common stock, which will be effective for trading purposes as of the commencement of trading on Thursday, July 28, 2016.
2016-12-31
2016-11-07 816.94 未披露 定期报告 2016-11-01
2016-11-07 818.19 1.00
更多>>
From December 31, 2015 to September 30, 2016 Equity-based compensation expense Proceeds from issuance of common stock Caladrius Biosciences, Inc., a cell therapy company combining an industry-leading development and manufacturing services provider (PCT) with a select therapeutic development pipeline, announces today that as of 5:00 p.m., Eastern Time, on July 27, 2016 it will effect a 1-for-10 reverse stock split of its outstanding common stock, which will be effective for trading purposes as of the commencement of trading on Thursday, July 28, 2016.
2016-09-30
2016-08-09 591.44 未披露 定期报告 2016-08-05
2016-08-09 592.67 1.00
更多>>
from December 31, 2015 to July 28, 2016 Equity-based compensation expense Proceeds from issuance of common stock Caladrius Biosciences, Inc., a cell therapy company combining an industry-leading development and manufacturing services provider (PCT) with a select therapeutic development pipeline, announces today that as of 5:00 p.m., Eastern Time, on July 27, 2016 it will effect a 1-for-10 reverse stock split of its outstanding common stock, which will be effective for trading purposes as of the commencement of trading on Thursday, July 28, 2016.
2016-07-28
2016-05-05 5903.35 未披露 定期报告 2016-05-05
2016-05-10 5901.25 未披露 定期报告 2016-04-22
2016-05-05 5912.33 1.00
更多>>
from December 31, 2015 to March 31, 2016 Share-based compensation Proceeds from issuance of common stock
2016-03-31
2016-03-15 5903.06 未披露 定期报告 2016-03-14
2016-03-15 5673.30 1.00
更多>>
From December 31, 2014 to December 31, 2015 Share-based compensation Net proceeds from issuance of common stock
2015-12-31
2015-11-05 5537.33 未披露 定期报告 2015-11-04
2015-11-05 5549.72 1.00
更多>>
from December 31, 2014 to September 30, 2015 Equity-based compensation Net proceeds from issuance of common stock
2015-09-30
2015-08-06 5534.97 1.00 定期报告 2015-08-05
2015-08-06 5545.30 1.00
更多>>
from December 31, 2014 to June 30, 2015 Equity-based compensation Net proceeds from issuance of common stock
2015-06-30
2015-05-06 4015.14 未披露 定期报告 2015-05-04
2015-04-30 3943.14 未披露 定期报告 2015-04-23
2015-05-06 3942.39 1.00
更多>>
from December 31, 2014 to March 31, 2015 Equity-based compensation Net proceeds from issuance of common stock
2015-03-31
2015-03-02 3845.93 未披露 定期报告 2015-02-27
2015-03-02 3678.39 1.00
更多>>
from December 31, 2013 to December 31, 2014 Share-based compensation Net proceeds from issuance of common stock Proceeds from option exercises Proceeds from warrant exercises Shares issued in CSC merger
2014-12-31
2014-10-30 3573.84 未披露 定期报告 2014-10-30
2014-10-30 3548.55 1.00
更多>>
from December 31, 2013 to September 30, 2014 Equity-based compensation Net proceeds from issuance of common stock Proceeds from option exercises Proceeds from warrant exercises Shares issued in CSC acquisition
2014-09-30
2014-08-29 3531.36 未披露 定期报告 2014-08-18
2014-08-07 3525.20 未披露 定期报告 2014-08-07
2014-08-07 3493.92 1.00
更多>>
from December 31, 2013 to June 30, 2014 Equity-based compensation Net proceeds from issuance of common stock Proceeds from option exercises Proceeds from warrant exercises Shares issued in CSC acquisition
2014-06-30
2014-06-12 3406.20 1.00 定期报告 2014-06-09
2014-05-08 3400.89 未披露
更多>>
On May 8, 2014, pursuant to the Company's acquisition of CSC, the Company issued an aggregate of 5,329,593 shares of the Company's restricted common stock.
2014-05-08
2014-05-08 2859.34 1.00
更多>>
from December 31, 2013 to March 31, 2014 Equity-based compensation Net proceeds from issuance of common stock Proceeds from option exercises Proceeds from warrant exercises
2014-03-31
2014-03-13 2858.26 未披露 定期报告 2014-03-11
2014-03-13 2719.65 1.00
更多>>
from December 31, 2012 to December 31, 2013 Share-based compensation Net proceeds from issuance of common stock Proceeds from option exercises Proceeds from warrant exercises
2013-12-31
2013-11-07 2714.19 未披露 定期报告 2013-11-06
2013-11-07 2119.39 1.00
更多>>
from December 31, 2012 to September 30, 2013 Share-based compensation Net proceeds from issuance of common stock Proceeds from option exercises Proceeds from warrant exercises
2013-09-30
2013-08-30 2033.68 1.00 定期报告 2013-08-19
2013-08-08 2031.73 未披露 定期报告 2013-08-07
2013-10-04 2619.39 未披露 定期报告 2013-08-05
2013-08-08 1958.44 1.00
更多>>
from December 31, 2012 to June 30, 2013 Share-based compensation Net proceeds from issuance of common stock Proceeds from warrant exercises
2013-06-30
2013-05-09 19379.95 未披露 定期报告 2013-05-09
2013-05-09 17027.87 1.00
更多>>
from December 31, 2012 to March 31, 2013 Share-based compensation Proceeds from issuance of common stock Proceeds from warrant exercises
2013-03-31
2013-03-11 16841.22 未披露 定期报告 2013-03-08
2013-03-11 16375.37 1.00
更多>>
from December 31, 2011 to December 31, 2012 Share-based compensation Proceeds from issuance of common stock Proceeds from warrant exercises Repayment of Series E Preferred Principal and Dividends Warrant inducements
2012-12-31
2012-12-07 16077.86 未披露 定期报告 2012-12-03
2012-11-13 15941.46 未披露 定期报告 2012-11-13
2012-11-13 15514.11 314.54
更多>>
from December 31, 2011 to September 30, 2012 Share-based compensation Proceeds from issuance of common stock Proceeds from warrant exercises Repayment of Series E Preferred Principal and Dividends Warrant inducements
2012-09-30
2012-09-07 15351.65 1.00 定期报告 2012-08-24
2012-08-24 15261.03 392.93 定期报告 2012-08-17
2012-08-14 15253.51 未披露 定期报告 2012-08-10
2012-08-14 13761.99 432.12
更多>>
from Dec 31,2011 to June 30,2012 Share-based compensation Proceeds from issuance of common stock Repayment of Series E Preferred Principal and Dividends
2012-06-30
2012-05-11 13260.35 未披露 定期报告 2012-05-04
2012-05-11 12988.71 549.70
更多>>
from December 31, 2011 to March 31, 2012 Share-based compensation Proceeds from issuance of common stock Repayment of Series E Preferred Principal and Dividends
2012-03-31
2012-03-20 11434.84 未披露 定期报告 2012-03-12
2012-03-20 10932.96 667.27
更多>>
from December 31, 2010 to December 31, 2011 Exercise of stock options Share-based compensation Proceeds from issuance of common stock Repayment of Series E Preferred Principal and Dividends Shares issued in PCT Merger Shares issued in Amorcyte Merger
2011-12-31
2011-11-10 10732.46 未披露 定期报告 2011-11-08
2011-11-10 10036.14 784.85 定期报告 2011-09-30
2011-08-12 9804.84 未披露 定期报告 2011-08-10
2011-08-12 8224.73 902.43 定期报告 2011-06-30
2011-05-17 8032.82 未披露 定期报告 2011-05-12
2011-05-17 7857.00 1020.01 定期报告 2011-03-31
2011-04-06 7856.42 未披露 定期报告 2011-03-30
2011-04-06 6422.11 1059.20
更多>>
from December 31, 2009 to December 31, 2010 Exercise of stock options Exercise of warrants Share-based compensation Proceeds from issuance of common stock Conversion of Series C preferred Shares issued for charitable contribution
2010-12-31
2010-11-12 5761.49 未披露 定期报告 2010-11-11
2010-11-12 5761.38 818.75 定期报告 2010-09-30
2010-08-16 5700.15 未披露 定期报告 2010-08-16
2010-08-16 5667.55 818.75 定期报告 2010-06-30
2010-05-17 5303.41 未披露 定期报告 2010-05-17
2010-05-17 4394.71 818.75 定期报告 2010-03-31
2010-03-31 4394.60 未披露 定期报告 2010-03-24
2010-03-31 3719.35 818.75
更多>>
from December 31, 2008 to December 31, 2009 Issuance of common stock to officers and directors Issuance of common stock to staff for compensation Issuance of restricted common stock for compensation Issuance of common stock for services Issuance of restricted common stock for services Conversions of Series D Preferred Common stock issued in CBH Merger
2009-12-31
2009-03-31 774.94 未披露 定期报告 2009-03-27
2009-03-31 771.50 1.00
更多>>
from December 31, 2007 to December 31, 2008 Issuance of Common Stock for cash, net of offering costs Issuance of Common Stock to officers and directors Issuance of restricted Common Stock for services Issuance of Common Stock to staff for compensation Issuance of Common Stock for services Exercise of Common Stock options Issuance of Common Stock to pay debt Forfeiture of restricted Common Stock Other adjustments
2008-12-31
2008-03-28 507.37 未披露 定期报告 2008-03-28
2008-03-28 482.61 1.00
更多>>
from December 31. 2006 to December 31. 2007 Issuance of common stock for cash,net of offering costs Issuance of common stock to acquire Stem Cell Technologies, Inc. Issuance of common shares for capital commitment Issuance of common stock to officers and directors Issuance of restricted common stock for services Issuance of restricted common stock to officers and directors Issuance of common stock for services
2007-12-31
Subsequent to the stockholders’ approval, the Caladrius Board of Directors approved a reverse stock split of Caladrius’ common stock at a ratio of one new share for every fifteen shares outstanding. The reverse stock split will become effective today, September 14, 2022, at 5:00pm EST.
From March 31, 2022 to June 30, 2022 Net proceeds from issuance of common stock Share-based compensation
From December 31, 2021 to March 31, 2022 Share-based compensation
From December 31, 2020 to December 31, 2021 Share-based compensation Net proceeds from issuance of common stock and warrants Proceeds from option exercises
From June 30, 2021 to September 30, 2021 Share-based compensation
From March 31, 2021 to June 30, 2021 Net proceeds from issuance of common stock
from December 31, 2020 to March 31, 2021 Share-based compensation Net proceeds from issuance of common stock and warrants Proceeds from option exercises
1.Common Stock offered by this prospectus supplement 24,906,134 shares. 2.Unless the company indicate otherwise, all information in this prospectus is based on 31,895,977 shares of Common Stock, which includes 19,395,977 shares of Common Stock outstanding as of September 30, 2020, plus 12,500,000 shares of Common Stock that were issued in a private placement offering on January 21, 2021.
From December 31, 2019 to December 31, 2020 Share-based compensation Net proceeds from issuance of common stock and warrants
From June 30, 2020 to September 30, 2020 Share-based compensation Net proceeds from issuance of common stock and warrants
From March 31, 2020 to June 30, 2020 Share-based compensation Net proceeds from issuance of common stock and warrants
1.Common Stock offered by this prospectus supplement 2,084,850 shares of Common Stock 2. based on 12,840,403 shares of Common Stock, which includes 10,627,691 shares of Common Stock outstanding as of March 31, 2020, plus 2,162,166 shares of Common Stock that were issued in a registered direct offering on April 23, 2020.
1.Common Stock offered by this prospectus supplement 2,162,166 shares of Common Stock 2.based on 10,627,691 shares of Common Stock outstanding as of March 31, 2020
from December 31, 2019 to March 31, 2020 Share-based compensation
from December 31, 2018 to December 31, 2019 Share-based compensation Net proceeds from issuance of common stock
From June 30, 2019 to September 30, 2019 Share-based compensation
From March 31, 2019 to June 30, 2019 Net proceeds from issuance of common stock
from December 31, 2018 to March 31, 2019 Share-based compensation Net proceeds from issuance of common stock
from December 31, 2017 to December 31, 2018 Share-based compensation Net proceeds from issuance of common stock Proceeds from option exercises
From December 31, 2017 to September 30, 2018 Share-based compensation Net proceeds from issuance of common stock Proceeds from option exercises
From December 31, 2017 to June 30, 2018 Share-based compensation Net proceeds from issuance of common stock Proceeds from option exercises
From December 31, 2017 to March 31, 2018 Share-based compensation Proceeds from option exercises
from December 31, 2016 to December 31, 2017 Share-based compensation Net proceeds from issuance of common stock Proceeds from option exercises
from December 31, 2016 to September 30, 2017 Share-based compensation Net proceeds from issuance of common stock Proceeds from option exercises
From December 31, 2016 to June 30, 2017 Share-based compensation Net proceeds from issuance of common stock Proceeds from option exercises
From December 31, 2016 to March 31, 2017 Share-based compensation Net proceeds from issuance of common stock
From December 31, 2015 to December 31, 2016 Share-based compensation Net proceeds from issuance of common stock Caladrius Biosciences, Inc., a cell therapy company combining an industry-leading development and manufacturing services provider (PCT) with a select therapeutic development pipeline, announces today that as of 5:00 p.m., Eastern Time, on July 27, 2016 it will effect a 1-for-10 reverse stock split of its outstanding common stock, which will be effective for trading purposes as of the commencement of trading on Thursday, July 28, 2016.
From December 31, 2015 to September 30, 2016 Equity-based compensation expense Proceeds from issuance of common stock Caladrius Biosciences, Inc., a cell therapy company combining an industry-leading development and manufacturing services provider (PCT) with a select therapeutic development pipeline, announces today that as of 5:00 p.m., Eastern Time, on July 27, 2016 it will effect a 1-for-10 reverse stock split of its outstanding common stock, which will be effective for trading purposes as of the commencement of trading on Thursday, July 28, 2016.
from December 31, 2015 to July 28, 2016 Equity-based compensation expense Proceeds from issuance of common stock Caladrius Biosciences, Inc., a cell therapy company combining an industry-leading development and manufacturing services provider (PCT) with a select therapeutic development pipeline, announces today that as of 5:00 p.m., Eastern Time, on July 27, 2016 it will effect a 1-for-10 reverse stock split of its outstanding common stock, which will be effective for trading purposes as of the commencement of trading on Thursday, July 28, 2016.
from December 31, 2015 to March 31, 2016 Share-based compensation Proceeds from issuance of common stock
From December 31, 2014 to December 31, 2015 Share-based compensation Net proceeds from issuance of common stock
from December 31, 2014 to September 30, 2015 Equity-based compensation Net proceeds from issuance of common stock
from December 31, 2014 to June 30, 2015 Equity-based compensation Net proceeds from issuance of common stock
from December 31, 2014 to March 31, 2015 Equity-based compensation Net proceeds from issuance of common stock
from December 31, 2013 to December 31, 2014 Share-based compensation Net proceeds from issuance of common stock Proceeds from option exercises Proceeds from warrant exercises Shares issued in CSC merger
from December 31, 2013 to September 30, 2014 Equity-based compensation Net proceeds from issuance of common stock Proceeds from option exercises Proceeds from warrant exercises Shares issued in CSC acquisition
from December 31, 2013 to June 30, 2014 Equity-based compensation Net proceeds from issuance of common stock Proceeds from option exercises Proceeds from warrant exercises Shares issued in CSC acquisition
On May 8, 2014, pursuant to the Company's acquisition of CSC, the Company issued an aggregate of 5,329,593 shares of the Company's restricted common stock.
from December 31, 2013 to March 31, 2014 Equity-based compensation Net proceeds from issuance of common stock Proceeds from option exercises Proceeds from warrant exercises
from December 31, 2012 to December 31, 2013 Share-based compensation Net proceeds from issuance of common stock Proceeds from option exercises Proceeds from warrant exercises
from December 31, 2012 to September 30, 2013 Share-based compensation Net proceeds from issuance of common stock Proceeds from option exercises Proceeds from warrant exercises
from December 31, 2012 to June 30, 2013 Share-based compensation Net proceeds from issuance of common stock Proceeds from warrant exercises
from December 31, 2012 to March 31, 2013 Share-based compensation Proceeds from issuance of common stock Proceeds from warrant exercises
from December 31, 2011 to December 31, 2012 Share-based compensation Proceeds from issuance of common stock Proceeds from warrant exercises Repayment of Series E Preferred Principal and Dividends Warrant inducements
from December 31, 2011 to September 30, 2012 Share-based compensation Proceeds from issuance of common stock Proceeds from warrant exercises Repayment of Series E Preferred Principal and Dividends Warrant inducements
from Dec 31,2011 to June 30,2012 Share-based compensation Proceeds from issuance of common stock Repayment of Series E Preferred Principal and Dividends
from December 31, 2011 to March 31, 2012 Share-based compensation Proceeds from issuance of common stock Repayment of Series E Preferred Principal and Dividends
from December 31, 2010 to December 31, 2011 Exercise of stock options Share-based compensation Proceeds from issuance of common stock Repayment of Series E Preferred Principal and Dividends Shares issued in PCT Merger Shares issued in Amorcyte Merger
from December 31, 2009 to December 31, 2010 Exercise of stock options Exercise of warrants Share-based compensation Proceeds from issuance of common stock Conversion of Series C preferred Shares issued for charitable contribution
from December 31, 2008 to December 31, 2009 Issuance of common stock to officers and directors Issuance of common stock to staff for compensation Issuance of restricted common stock for compensation Issuance of common stock for services Issuance of restricted common stock for services Conversions of Series D Preferred Common stock issued in CBH Merger
from December 31, 2007 to December 31, 2008 Issuance of Common Stock for cash, net of offering costs Issuance of Common Stock to officers and directors Issuance of restricted Common Stock for services Issuance of Common Stock to staff for compensation Issuance of Common Stock for services Exercise of Common Stock options Issuance of Common Stock to pay debt Forfeiture of restricted Common Stock Other adjustments
from December 31. 2006 to December 31. 2007 Issuance of common stock for cash,net of offering costs Issuance of common stock to acquire Stem Cell Technologies, Inc. Issuance of common shares for capital commitment Issuance of common stock to officers and directors Issuance of restricted common stock for services Issuance of restricted common stock to officers and directors Issuance of common stock for services
同花顺个股页面 | 模拟炒股 | 股民学校 | 手机炒股| 联系我们

免责声明:本信息由同花顺金融研究中心提供，仅供参考，同花顺金融研究中心力求但不保证数据的完全准确，如有错漏请以中国证监会指定上市公司信息披露媒体为准，同花顺金融研究中心不对因该资料全部或部分内容而引致的盈亏承担任何责任。用户个人对服务的使用承担风险。同花顺对此不作任何类型的担保。同花顺不担保服务一定能满足用户的要求，也不担保服务不会受中断，对服务的及时性，安全性，出错发生都不作担保。同花顺对在同花顺上得到的任何信息服务或交易进程不作担保。同花顺提供的包括同花顺理财的所有文章，数据，不构成任何的投资建议，用户查看或依据这些内容所进行的任何行为造成的风险和结果都自行负责，与同花顺无关。

【免责声明】本产品中的行情数据及资讯信息来源于第三方，长江证券不对收集数据的版权、真实性、准确性及传输过程中发生的传送错误承担法律责任。本内容仅供参考，不作为投资决策依据，长江证券不对因据此操作产生的盈亏承担任何责任。投资有风险，入市需谨慎。